The US Federal Trade Commission (FTC) has issued final changes to the premerger notification rules that require pharmaceutical companies to report certain proposed patent right acquisitions to the commission and US Department of Justice (DoJ) for antitrust review.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
FTC, DoJ, patent rights, premerger notification rules